Pfizer PFE
US equityMarket cap rank #116Drug Manufacturers - GeneralCAR-T TherapyInfectious DiseaseCancer Research
$29.39 −$0.06 (-0.20%)
Market closed · Nov 9, 1:50 am ET · Last extended-hours $29.35 -0.14%
Open$29.07
Prev close$29.45
Day range$28.54 – $29.43
Volume48.32M
Market cap$167.52B
P/E (TTM)42.0
Dividend yield5.85%
Earnings
Average move on report day±2.1%last 16 reports
Closed higher9 of 1656% of the time
Best reaction+6.1%
Worst reaction-3.3%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q2 | 4 Aug 2026 | None | ±2.4% | +1.52% | Within range |
| 2026/Q1 | 5 May 2026 | None | ±3.6% | +0.57% | Within range |
| 2025/Q4 | 3 Feb 2026 | None | ±3.0% | -3.34% | Bigger than priced |
| 2025/Q3 | 4 Nov 2025 | Pre Market | ±4.0% | -1.46% | Within range |
| 2025/Q2 | 5 Aug 2025 | None | ±5.0% | +5.18% | Bigger than priced |
| 2025/Q1 | 29 Apr 2025 | None | ±4.3% | +3.21% | Within range |
| 2024/Q4 | 4 Feb 2025 | Pre Market | ±4.6% | -1.26% | Within range |
| 2024/Q3 | 29 Oct 2024 | None | ±4.1% | -1.39% | Within range |
| 2024/Q2 | 30 Jul 2024 | None | ±5.1% | +2.18% | Within range |
| 2024/Q1 | 1 May 2024 | Pre Market | ±4.8% | +6.09% | Bigger than priced |
| 2023/Q4 | 30 Jan 2024 | Pre Market | ±4.2% | -1.67% | Within range |
| 2023/Q3 | 31 Oct 2023 | Pre Market | ±4.3% | +0.03% | Within range |
| 2023/Q2 | 1 Aug 2023 | None | ±3.7% | -1.25% | Within range |
| 2023/Q1 | 2 May 2023 | None | ±3.7% | -0.38% | Within range |
| 2022/Q4 | 31 Jan 2023 | None | ±4.8% | +1.40% | Within range |
| 2022/Q3 | 1 Nov 2022 | None | ±4.9% | +3.14% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Where the revenue comes from
Quarter 2026/Q2
By business line
Fundamentals
Latest reported quarter: Q2, ended Jun 2026
Revenue$15.03B+2.6% YoY
Operating profit$3.54B-6.1% YoY
Net profit-$237.00M-108.1% YoY
Diluted EPS-$0.04-107.8% YoY
Free cash flow$302.00M+125.2% YoY
Operating cash flow$835.00M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin73.2%
Operating margin26.7%
Net margin6.8%
Return on equity5.0%
Return on assets2.1%
Return on invested capital3.8%
Current ratio1.27
Liabilities / assets57.5%
Cash & investments$11.70B
Total debt$63.19B
Net cash (debt)-$51.50B
Free cash flow / sales17.2%
No comments yet — be the first to weigh in on PFE.
Sign in to join the discussion.